Amendment No. 1 to Cell Line License Agreement, by and between the registrant and WuXi Biologics (Hong Kong) Limited, dated January 12, 2021
CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***],
HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE
THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
AMENDMENT NO. 1 TO CELL LINE LICENSE AGREEMENT
This Amendment No. 1 (this Amendment) is entered into between Silverback Therapeutics, Inc. (Licensee) and WuXi Biologics (Hong Kong) Limited (WuXi Biologics), effective as of the date of the last signature hereto, and amends, as set forth herein, the Cell Line License Agreement (the CLLA), effective as of 11 October, 2019 entered into between Licensee and WuXi Biologics. Each of WuXi Biologics and Licensee are referred to from time to time as a Party and collectively as the Parties. All terms used, but not otherwise defined, in this Amendment shall have the meanings accorded to them in the CLLA.
1. The Parties hereby agree to amend the Appendix I pursuant to Section 1.2 of the CLLA as follows:
List of Service Agreements for Licensee Products
Ratification of Agreement. The CLLA is in all respects ratified and confirmed by the Parties.
One Instrument. The CLLA and this Amendment shall be read, taken and construed as one and the same document.
Counterpart Signatures. This Amendment may be signed by the Parties in multiple, separate counterparts which when taken together shall constitute one and the same
***Certain Information Omitted
Page 1 of 2
|document. This Agreement may be signed by electronic signature via a recognized provider (e.g., DocuSign or Adobe) or .pdf file and such signature shall be deemed to bind each Party hereto as if they were original.|
IN WITNESS WHEREOF, the Parties have signed this Amendment through their duly authorized representatives.
|WuXi Biologics (Hong Kong) Limited||Silverback Therapeutics, Inc.|
Page 2 of 2